Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer.
Serum thyroid-stimulating hormone (TSH), free thyroxine (FT4) and total tri-iodothyronine (TT3) concentrations were measured in 45 postmenopausal breast cancer patients before adjuvant treatment with tamoxifen and at 3- and 6-month intervals. A significant increase in TSH (p = 0.002) at the end of 3 months and a subsequent decrease at the end of 6 months was noted. There were no significant changes in TT3 and FT4. We concluded that tamoxifen therapy in postmenopausal women may result in a reversible increase in TSH after 3 months.
Zidan
J
J
Oncology Unit, Rebecca Sieff Government Hospital, Safed, Israel.
Rubenstein
W
W
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D013629:Tamoxifen / Q000494:pharmacology*; D013960:Thyroid Function Tests; D013961:Thyroid Gland / Q000187:drug effects* / Q000503:physiopathology; D013963:Thyroid Hormones / Q000097:blood*
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013963:Thyroid Hormones; D013629:Tamoxifen